BioVie Announces FDA Authorization Of Investigational New Drug Application For Phase 2 Trial To Evaluate Bezisterim In Long COVID; Authorization Puts Co. On Track To Receive Additional $12.6M Grand From US DOD And Initiate Phase 2 Trial
Portfolio Pulse from Benzinga Newsdesk
BioVie has received FDA authorization for an investigational new drug application to conduct a Phase 2 trial of Bezisterim for Long COVID. This authorization enables the company to receive an additional $12.6 million grant from the US Department of Defense and proceed with the trial.
September 03, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioVie has received FDA authorization for a Phase 2 trial of Bezisterim for Long COVID, which also unlocks a $12.6 million grant from the US DOD.
The FDA authorization is a significant regulatory milestone for BioVie, allowing them to advance their clinical trial for Bezisterim. This also triggers a substantial grant from the US DOD, providing financial support and validating the potential of their treatment. Such developments are likely to positively impact BioVie's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100